CQS Cayman’s Ultragenyx Pharmaceutical RARE Stock Holding History

CQS Cayman’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-64,300	Closed	-$4.07M	–	140
2016 Q1	$4.07M	Buy	+64,300	New	+$4.21M	0.41%	53
2015 Q4	–	Sell	-45,000	Closed	-$4.33M	–	167
2015 Q3	$4.33M	Buy	45,000 +20,000	+80%	+$2.29M	0.36%	66
2015 Q2	$2.56M	Sell	25,000 -45,000	-64%	-$3.49M	0.15%	100
2015 Q1	$4.35M	Buy	+70,000	New	+$3.89M	0.2%	88

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

CQS Cayman's RARE Position: Q2 2016 in Review

CQS Cayman sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2016, closing a stake of 64,300 shares — an estimated $4.07M sold.

CQS Cayman first reported a position in RARE in Q1 2015 and held it in 4 quarters. The position peaked at $4.35M in Q1 2015. 161 funds tracked by Wall St. Rank hold RARE as of Q2 2016.

CQS Cayman reported no remaining Ultragenyx Pharmaceutical position as of Q2 2016 after selling out during the quarter.
CQS Cayman sold 64,300 Ultragenyx Pharmaceutical shares in Q2 2016, an estimated $4.07M.
CQS Cayman first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and held it in 4 quarters.
CQS Cayman's Ultragenyx Pharmaceutical position peaked at $4.35M in Q1 2015.
161 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2016.

Based on CQS Cayman's 13F filing for Q2 2016, filed 9 Aug 2016.